Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of GSK3542503 vs Moduretic in Healthy Adults
NCT03031496Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydrochlorothiazide + amiloride in hypertension (HTN), heart failure (HF) and Liver cirrhosis (LC) (2 arms), sponsored by GSK. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration at Day 3 and Maximum Observed Plasma Concentration at Day 3. Started Mar 2017; status: completed.
02
Drugs
hydrochlorothiazide + amiloride
03
Conditions
hypertension (HTN)heart failure (HF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03031496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031496.